These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1718045)

  • 21. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
    Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
    Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
    Roach M
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Radiochemotherapy and simultaneous hormonal therapy of locally advanced prostatic carcinoma].
    Strnad V; Riepl M; Kühn R; Sauer R
    Strahlenther Onkol; 1996 Apr; 172(4):225-8. PubMed ID: 8623086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Possibilities in drug therapy in prostatic carcinoma].
    Schmid HP
    Ther Umsch; 1995 Jun; 52(6):418-22. PubMed ID: 7541571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR; Presti JC; Gill H; Brooks J; Hancock SL
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical protocols in treatment of prostatic carcinoma in Europe. The role of EORTC and other organizations].
    Newling DW
    Urologe A; 1995 Sep; 34(5):374-81. PubMed ID: 7483153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
    Isaacs JT
    Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Established and new urological therapeutic options in the management of prostate carcinoma].
    Michel MS; Trojan L; Knoll T; Bross S; Alken P
    Radiologe; 2003 Jun; 43(6):441-7. PubMed ID: 12827258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.
    Cheung R; Kamat AM; de Crevoisier R; Allen PK; Lee AK; Tucker SL; Pisters L; Babaian RJ; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):134-40. PubMed ID: 16111581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Radiotherapy of prostatic cancer and its administration in the prehospital period of patient management].
    Makarova GV; Ratner TG; Cheban NL; Kobzev SD; Gurariĭ LL; Romanov VA; Arkad'ev AM; Gorilovskiĭ LM
    Ross Med Zh; 1992; (2):48-50. PubMed ID: 1643340
    [No Abstract]   [Full Text] [Related]  

  • 38. Hormonal therapy of prostatic carcinoma. Defining the challenge.
    Crawford ED
    Cancer; 1990 Sep; 66(5 Suppl):1035-8. PubMed ID: 2203516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer.
    Fellows GJ; Clark PB; Beynon LL; Boreham J; Keen C; Parkinson MC; Peto R; Webb JN
    Br J Urol; 1992 Sep; 70(3):304-9. PubMed ID: 1422689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Problems and principles of hormone therapy of advanced prostate cancer].
    Altwein JE; Faul P
    Klin Wochenschr; 1990 Apr; 68(7):347-58. PubMed ID: 1692896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.